Antitumor activity of sorafenib and imatinib in a patient with thymic carcinoma harboring c-KIT exon 13 missense mutation K642E

類似資料

• Antitumor activity of sorafenib and imatinib in a patient with thymic carcinoma harboring c-KIT exon 13 missense mutation K642E
  著者:: Catania C, 等
  出版事項: (2014-05-01)
• Inactivity of imatinib in gastrointestinal stromal tumors (GISTs) harboring a KIT activation-loop domain mutation (exon 17 mutation pN822K)
  著者:: Spitaleri, Gianluca, 等
  出版事項: (2015)
• Inactivity of imatinib in gastrointestinal stromal tumors (GISTs) harboring a KIT activation-loop domain mutation (exon 17 mutation pN822K)
  著者:: Spitaleri G, 等
  出版事項: (2015-08-01)
• Phase Ib of Sorafenib in Combination With Everolimus in Patients With Advanced Solid Tumors, Selected on the Basis of Molecular Targets
  著者:: Toffalorio, Francesca, 等
  出版事項: (2014)
• Afatinib in first-line setting for NSCLC harbouring common EGFR mutations: new light after the preliminary results of LUX-Lung 7?
  著者:: Passaro, Antonio, 等
  出版事項: (2016)